Angiotensin II-Induced End-Organ Damage in Mice Is Attenuated by Human Exosomes and by an Exosomal Y RNA Fragment

Overview

Journal Hypertension

Date 2018 Jun 6

PMID 29866742

Citations 34

Authors

Linda Cambier

Jorge F Giani

Weixin Liu

Takeshi Ijichi

Antonio K Echavez

Jackelyn Valle

Eduardo Marban

Affiliations

Soon will be listed here.

Abstract

Hypertension often leads to cardiovascular disease and kidney dysfunction. Exosomes secreted from cardiosphere-derived cells (CDC-exo) and their most abundant small RNA constituent, the Y RNA fragment EV-YF1, exert therapeutic benefits after myocardial infarction. Here, we investigated the effects of CDC-exo and EV-YF1, each administered individually, in a model of cardiac hypertrophy and kidney injury induced by chronic infusion of Ang (angiotensin) II. After 2 weeks of Ang II, multiple doses of CDC-exo or EV-YF1 were administered retro-orbitally. Ang II infusion induced an elevation in systolic blood pressure that was not affected by CDC-exo or EV-YF1. Echocardiography confirmed that Ang II infusion led to cardiac hypertrophy. CDC-exo and EV-YF1 both attenuated cardiac hypertrophy and reduced cardiac inflammation and fibrosis. In addition, both CDC-exo and EV-YF1 improved kidney function and diminished renal inflammation and fibrosis. The beneficial effects of CDC-exo and EV-YF1 were associated with changes in the expression of the anti-inflammatory cytokine IL (interleukin)-10 in plasma, heart, spleen, and kidney. In summary, infusions of CDC-exo or EV-YF1 attenuated cardiac hypertrophy and renal injury induced by Ang II infusion, without affecting blood pressure, in association with altered IL-10 expression. Exosomes and their defined noncoding RNA contents may represent potential new therapeutic approaches for hypertension-associated cardiovascular and renal damage.

Citing Articles

Emerging role of sphingolipids and extracellular vesicles in development and therapeutics of cardiovascular diseases.

Bhat O, Mir R, Nehvi I, Wani N, Dar A, Zargar M Int J Cardiol Heart Vasc. 2024; 53:101469.

PMID: 39139609 PMC: 11320467. DOI: 10.1016/j.ijcha.2024.101469.

Exosomal miR-15a-5p from cardiomyocytes promotes myocardial fibrosis.

Cao F, Li Z, Ding W, Qv C, Zhao H Mol Cell Biochem. 2024; 480(3):1701-1713.

PMID: 39110279 DOI: 10.1007/s11010-024-05080-3.

Adult cardiomyocytes-derived EVs for the treatment of cardiac fibrosis.

Prieto-Vila M, Yoshioka Y, Kuriyama N, Okamura A, Yamamoto Y, Muranaka A J Extracell Vesicles. 2024; 13(7):e12461.

PMID: 38940266 PMC: 11211925. DOI: 10.1002/jev2.12461.

TDO2-augmented fibroblasts secrete EVs enriched in immunomodulatory Y-derived small RNA.

Ciullo A, Peck K, Jones X, Yamaguchi S, Morris A, Kumar A J Extracell Biol. 2024; 2(2):e73.

PMID: 38938522 PMC: 11080885. DOI: 10.1002/jex2.73.

Y4 RNA fragments from cardiosphere-derived cells ameliorate diabetic myocardial ischemia‒reperfusion injury by inhibiting protein kinase C β-mediated macrophage polarization.

Liu D, Luo X, Lu C, Feng Y, Chen D, Zeng Z Cardiovasc Diabetol. 2024; 23(1):202.

PMID: 38867293 PMC: 11170846. DOI: 10.1186/s12933-024-02247-6.

References

Hogg J, Collins K . Human Y5 RNA specializes a Ro ribonucleoprotein for 5S ribosomal RNA quality control. Genes Dev. 2007; 21(23):3067-72. PMC: 2081973. DOI: 10.1101/gad.1603907. View

Gallet R, Dawkins J, Valle J, Simsolo E, de Couto G, Middleton R . Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J. 2017; 38(3):201-211. PMC: 5837390. DOI: 10.1093/eurheartj/ehw240. View

Teunissen S, Kruithof M, Farris A, Harley J, Venrooij W, Pruijn G . Conserved features of Y RNAs: a comparison of experimentally derived secondary structures. Nucleic Acids Res. 1999; 28(2):610-9. PMC: 102524. DOI: 10.1093/nar/28.2.610. View

Hall A, Dalmay T . Discovery of novel small RNAs in the quest to unravel genome complexity. Biochem Soc Trans. 2013; 41(4):866-70. DOI: 10.1042/BST20120347. View

Tseliou E, Reich H, de Couto G, Terrovitis J, Sun B, Liu W . Cardiospheres reverse adverse remodeling in chronic rat myocardial infarction: roles of soluble endoglin and Tgf-β signaling. Basic Res Cardiol. 2014; 109(6):443. DOI: 10.1007/s00395-014-0443-8. View

Johnston B, Owen D . Tissue blood flow and distribution of cardiac output in cats: changes caused by intravenous infusions of histamine and histamine receptor agonists. Br J Pharmacol. 1977; 60(2):173-80. PMC: 1667415. DOI: 10.1111/j.1476-5381.1977.tb07738.x. View

Crowley S, Gurley S, Herrera M, Ruiz P, Griffiths R, Kumar A . Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006; 103(47):17985-90. PMC: 1693859. DOI: 10.1073/pnas.0605545103. View

Wang Y, Li Y, Wu Y, Jia L, Wang J, Xie B . 5TNF-α and IL-1β neutralization ameliorates angiotensin II-induced cardiac damage in male mice. Endocrinology. 2014; 155(7):2677-87. DOI: 10.1210/en.2013-2065. View

Dhahbi J, Spindler S, Atamna H, Boffelli D, Martin D . Deep Sequencing of Serum Small RNAs Identifies Patterns of 5' tRNA Half and YRNA Fragment Expression Associated with Breast Cancer. Biomark Cancer. 2014; 6:37-47. PMC: 4260766. DOI: 10.4137/BIC.S20764. View

10.

Jin Y, Liu R, Xie J, Xiong H, He J, Chen N . Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model. Lab Invest. 2013; 93(7):801-11. DOI: 10.1038/labinvest.2013.64. View

11.

Swirski F, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P . Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009; 325(5940):612-6. PMC: 2803111. DOI: 10.1126/science.1175202. View

12.

Rothermel B, Hill J . Myocyte autophagy in heart disease: friend or foe?. Autophagy. 2007; 3(6):632-4. DOI: 10.4161/auto.4913. View

13.

Hendrick J, Wolin S, Rinke J, Lerner M, Steitz J . Ro small cytoplasmic ribonucleoproteins are a subclass of La ribonucleoproteins: further characterization of the Ro and La small ribonucleoproteins from uninfected mammalian cells. Mol Cell Biol. 1981; 1(12):1138-49. PMC: 369740. DOI: 10.1128/mcb.1.12.1138-1149.1981. View

14.

Bernardo B, Weeks K, Pretorius L, McMullen J . Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. 2010; 128(1):191-227. DOI: 10.1016/j.pharmthera.2010.04.005. View

15.

Reid I, Morris B, Ganong W . The renin-angiotensin system. Annu Rev Physiol. 1978; 40:377-410. DOI: 10.1146/annurev.ph.40.030178.002113. View

16.

Wolf G, Jablonski K, Schroeder R, Reinking R, Shankland S, Stahl R . Angiotensin II-induced hypertrophy of proximal tubular cells requires p27Kip1. Kidney Int. 2003; 64(1):71-81. DOI: 10.1046/j.1523-1755.2003.00076.x. View

17.

Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio M . Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009; 4(2):337-44. PMC: 2637601. DOI: 10.2215/CJN.03530708. View

18.

de Couto G, Liu W, Tseliou E, Sun B, Makkar N, Kanazawa H . Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction. J Clin Invest. 2015; 125(8):3147-62. PMC: 4563759. DOI: 10.1172/JCI81321. View

19.

Kwon W, Cha H, Heo J, Choi J, Jang B, Lee I . Interleukin-10 deficiency aggravates angiotensin II-induced cardiac remodeling in mice. Life Sci. 2016; 146:214-21. DOI: 10.1016/j.lfs.2016.01.022. View

20.

Kobori H, Nangaku M, Navar L, Nishiyama A . The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007; 59(3):251-87. DOI: 10.1124/pr.59.3.3. View